AIM — AIM ImmunoTech Inc.
Is AIM overbought or oversold? Here is the current MarketMoodz read.
AIM ImmunoTech Inc. (AIM) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.13. The rating moved from Oversold to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.13
- Last changeMoved from Oversold to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
AIM ImmunoTech Inc. (AIM) is a micro‑cap clinical biotech with a concentrated immunomodulatory pipeline and limited financial resources. The company’s near‑term profile is highly binary: upside depends on successful clinical/regulatory catalysts or strategic partnerships, while downside is driven by cash burn, likely dilution, thin liquidity and sector financing pressure. Public information coverage is sparse, increasing informational risk.
Key factors
- Small-cap clinical-stage biotech profile with a concentrated immunotherapy/antiviral pipeline, making performance highly binary and catalyst-driven.
- Weak financial profile typical of microcap biotechs: recurring operating losses, limited revenue generation, and likely need for near-term financing.
- Thin liquidity and low trading volume, increasing volatility and making large moves from retail or block trades more likely.
- Sector readthroughs (convertible-debt and financing pressure) increase the chance of dilutive financings for mid-/small-cap biotech issuers.
- Absence of recent EDGAR/robust social or research coverage reduces informational transparency for investors and heightens uncertainty.
- Potential upside catalysts exist (clinical readouts, regulatory decisions, licensing/partnership deals) but are binary and timing-uncertain.
Risks
- Near-term dilution from equity financings or convertible instruments that can materially reduce per-share value.
- Clinical-trial failure or negative regulatory feedback for pipeline candidates, which would likely cause steep share price declines.
- Ongoing cash burn with limited revenue; inability to secure non-dilutive financing would pressure operations.
- Extreme price volatility and low liquidity that can amplify losses for holders and complicate exit strategies.
- Adverse macro/sector flows away from risk assets and small biotech names can exacerbate downside in the absence of positive news.
- Reputational, compliance, or manufacturing/regulatory risks that are common to small biotech firms with limited infrastructure.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AIM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.